Senate panel advances legislation capping private insurance insulin at $35
- Bipartisan legislation to cap the cost of insulin at $35 for people with private health insurance advanced through a key Senate committee Wednesday, but its future remains uncertain.
- The measure cleared the Senate Health, Education, Labor and Pensions Committee by a bipartisan 17-5 vote, with six Republicans joining every Democrat on the panel.
Unverified
- Bipartisan legislation to cap the cost of insulin at $35 for people with private health insurance advanced through a key Senate committee Wednesday, but its future remains uncertain.
- The measure cleared the Senate Health, Education, Labor and Pensions Committee by a bipartisan 17-5 vote, with six Republicans joining every Democrat on the panel.
Sources: The Hill